119 related articles for article (PubMed ID: 22609219)
1. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
Chu EY; Wanat KA; Miller CJ; Amaravadi RK; Fecher LA; Brose MS; McGettigan S; Giles LR; Schuchter LM; Seykora JT; Rosenbach M
J Am Acad Dermatol; 2012 Dec; 67(6):1265-72. PubMed ID: 22609219
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous effects of BRAF inhibitor therapy: a case series.
Mattei PL; Alora-Palli MB; Kraft S; Lawrence DP; Flaherty KT; Kimball AB
Ann Oncol; 2013 Feb; 24(2):530-537. PubMed ID: 23035153
[TBL] [Abstract][Full Text] [Related]
3. COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors.
Escuin-Ordinas H; Atefi M; Fu Y; Cass A; Ng C; Huang RR; Yashar S; Comin-Anduix B; Avramis E; Cochran AJ; Marais R; Lo RS; Graeber TG; Herschman HR; Ribas A
Mol Oncol; 2014 Mar; 8(2):250-60. PubMed ID: 24345644
[TBL] [Abstract][Full Text] [Related]
4. Topical 5-fluorouracil elicits regressions of BRAF inhibitor-induced cutaneous squamous cell carcinoma.
Viros A; Hayward R; Martin M; Yashar S; Yu CC; Sanchez-Laorden B; Zambon A; Niculescu-Duvaz D; Springer C; Lo RS; Marais R
J Invest Dermatol; 2013 Jan; 133(1):274-6. PubMed ID: 22895366
[No Abstract] [Full Text] [Related]
5. Presence of human polyomavirus 6 in mutation-specific BRAF inhibitor-induced epithelial proliferations.
Schrama D; Groesser L; Ugurel S; Hafner C; Pastrana DV; Buck CB; Cerroni L; Theiler A; Becker JC
JAMA Dermatol; 2014 Nov; 150(11):1180-6. PubMed ID: 24943872
[TBL] [Abstract][Full Text] [Related]
6. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Su F; Viros A; Milagre C; Trunzer K; Bollag G; Spleiss O; Reis-Filho JS; Kong X; Koya RC; Flaherty KT; Chapman PB; Kim MJ; Hayward R; Martin M; Yang H; Wang Q; Hilton H; Hang JS; Noe J; Lambros M; Geyer F; Dhomen N; Niculescu-Duvaz I; Zambon A; Niculescu-Duvaz D; Preece N; Robert L; Otte NJ; Mok S; Kee D; Ma Y; Zhang C; Habets G; Burton EA; Wong B; Nguyen H; Kockx M; Andries L; Lestini B; Nolop KB; Lee RJ; Joe AK; Troy JL; Gonzalez R; Hutson TE; Puzanov I; Chmielowski B; Springer CJ; McArthur GA; Sosman JA; Lo RS; Ribas A; Marais R
N Engl J Med; 2012 Jan; 366(3):207-15. PubMed ID: 22256804
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.
Cammareri P; Rose AM; Vincent DF; Wang J; Nagano A; Libertini S; Ridgway RA; Athineos D; Coates PJ; McHugh A; Pourreyron C; Dayal JH; Larsson J; Weidlich S; Spender LC; Sapkota GP; Purdie KJ; Proby CM; Harwood CA; Leigh IM; Clevers H; Barker N; Karlsson S; Pritchard C; Marais R; Chelala C; South AP; Sansom OJ; Inman GJ
Nat Commun; 2016 Aug; 7():12493. PubMed ID: 27558455
[TBL] [Abstract][Full Text] [Related]
8. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.
Cohen DN; Lawson SK; Shaver AC; Du L; Nguyen HP; He Q; Johnson DB; Lumbang WA; Moody BR; Prescott JL; Chandra PK; Boyd AS; Zwerner JP; Robbins JB; Tyring SK; Rady PL; Chappell JD; Shyr Y; Infante JR; Sosman JA
Clin Cancer Res; 2015 Jun; 21(11):2624-34. PubMed ID: 25724524
[TBL] [Abstract][Full Text] [Related]
9. Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.
Cohen PR; Bedikian AY; Kim KB
J Clin Aesthet Dermatol; 2013 May; 6(5):27-37. PubMed ID: 23710269
[TBL] [Abstract][Full Text] [Related]
10. Letter to the editors: Development of malignant melanoma and squamous cell carcinoma in a patient receiving fingolimod treatment.
Karabas M; Tepe N; Esmeli F
Neurol Sci; 2024 Jan; 45(1):359-360. PubMed ID: 37723372
[No Abstract] [Full Text] [Related]
11. Ophthalmic adverse effects of BRAF inhibitors.
Castillejo Becerra CM; Smith WM; Dalvin LA
Eur J Ophthalmol; 2022 Oct; ():11206721221132872. PubMed ID: 36217756
[TBL] [Abstract][Full Text] [Related]
12. Multiple Warty Dyskeratomas of the Scalp: A Case Report and Literature Review.
Shiraishi K; Sayama K
Ann Dermatol; 2023 Nov; 35(Suppl 2):S345-S346. PubMed ID: 38061738
[No Abstract] [Full Text] [Related]
13. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
[TBL] [Abstract][Full Text] [Related]
14. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
Sibaud V; Lamant L; Maisongrosse V; Delord JP
Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Mamolo C; Harness J; Tan H; Menter A
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks.
Anforth R; Carlos G; Clements A; Kefford R; Fernandez-Peñas P
Br J Dermatol; 2015 Jan; 172(1):239-43. PubMed ID: 25040674
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous toxicities of RAF inhibitors.
Anforth R; Fernandez-Peñas P; Long GV
Lancet Oncol; 2013 Jan; 14(1):e11-8. PubMed ID: 23276366
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
Chuk MK; Chang JT; Theoret MR; Sampene E; He K; Weis SL; Helms WS; Jin R; Li H; Yu J; Zhao H; Zhao L; Paciga M; Schmiel D; Rawat R; Keegan P; Pazdur R
Clin Cancer Res; 2017 Oct; 23(19):5666-5670. PubMed ID: 28235882
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
